Can I Take Creatine with PT-141 (Bremelanotide)?

What Is PT-141 (Bremelanotide) and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It binds MC3R and MC4R receptors in the central nervous system to modulate sexual desire pathways. The FDA approved it in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as a 1.75 mg subcutaneous injection taken 45 minutes before anticipated sexual activity.

FDA Approval and Labeled Use

The approval was supported by two Phase 3 trials, RECONNECT-1 and RECONNECT-2 (combined N=1,267), which showed statistically significant increases in satisfying sexual events and reductions in distress related to low desire versus placebo (fda.gov prescribing information). Off-label use in men targeting erectile dysfunction has grown substantially, driven by the drug's central rather than vascular mechanism, which differs from phosphodiesterase-5 inhibitors.

Pharmacokinetics Relevant to Supplement Interactions

After subcutaneous injection, bremelanotide reaches peak plasma concentration in approximately 1 hour. It is metabolized via hydrolysis of the peptide bond, not primarily via cytochrome P450 enzymes. That matters because most supplement-drug pharmacokinetic interactions run through CYP3A4, CYP2D6, or CYP1A2. Creatine does not meaningfully affect any of those enzymes, so a classical pharmacokinetic collision between the two is not expected (pubmed.ncbi.nlm.nih.gov/31116062).

Renal excretion accounts for roughly 64% of bremelanotide elimination. Any condition that impairs glomerular filtration rate (GFR) can slow clearance and raise systemic exposure.

What Is Creatine and Why Does It Affect Creatinine Levels?

Creatine monohydrate is one of the most extensively studied nutritional supplements in sports medicine. The body stores creatine in skeletal muscle as phosphocreatine; that reservoir is spontaneously and non-enzymatically converted to creatinine, which is then filtered and excreted by the kidneys.

The Creatine-to-Creatinine Conversion

When you supplement creatine, you expand the total creatine pool in muscle. More substrate means more spontaneous conversion to creatinine, so urinary creatinine excretion rises and serum creatinine creeps upward. A 2003 study in the Journal of the International Society of Sports Nutrition found that creatine loading (20 g/day for 5 days followed by 5 g/day maintenance) raised serum creatinine by a mean of 0.16 to 0.22 mg/dL in healthy subjects, representing roughly a 12 to 18% increase from baseline (pubmed.ncbi.nlm.nih.gov/14636102).

That rise is physiological, not pathological. It reflects increased substrate, not damaged nephrons. However, clinical laboratories flag serum creatinine above 1.2 mg/dL (men) or 1.0 mg/dL (women) as abnormal, and a creatine-induced bump can push a borderline result into the abnormal range.

Why That Matters for Kidney Function Assessment

Estimated GFR equations, including the widely used CKD-EPI formula, use serum creatinine as a primary input. A spuriously elevated creatinine due to creatine supplementation can lower the calculated eGFR, making someone appear to have mild chronic kidney disease when their kidneys are normal. If a prescriber orders renal labs to determine bremelanotide eligibility or to monitor ongoing safety, an undisclosed creatine supplement can produce a misleading picture.

The International Society of Sports Nutrition's 2017 position stand notes that creatine supplementation "may produce falsely elevated creatinine values" and recommends that clinicians be informed of creatine use before interpreting renal function panels (pubmed.ncbi.nlm.nih.gov/28615996).

Is There a Direct Pharmacokinetic Interaction Between Creatine and Bremelanotide?

No. The two agents do not share metabolic pathways in a clinically meaningful way.

CYP Enzyme Involvement

Bremelanotide is not primarily a CYP substrate. The prescribing information notes that in vitro studies show it is a weak inhibitor of CYP1A2 and an inducer of CYP3A4, but these effects are modest at clinical doses (accessdata.fda.gov). Creatine is not metabolized by CYP enzymes at all; it is converted to creatinine through a spontaneous, non-enzymatic reaction. No competitive inhibition, no induction, no displacement from plasma proteins.

Protein Binding and Volume of Distribution

Bremelanotide has low plasma protein binding (approximately 21%). Creatine in circulation is largely unbound and taken up rapidly by muscle transporters. There is no plausible displacement interaction. Bioavailability of bremelanotide is not altered by gut absorption of creatine because they do not share intestinal transporters.

Renal Clearance Overlap

This is the closest to an interaction, and it is still indirect. Both creatinine (the creatine metabolite) and bremelanotide compete for filtration and, to a lesser degree, tubular secretion. The clinical significance of that shared renal pathway at standard doses is probably low. But in someone with already reduced eGFR, even mild additional competition at the tubular level could marginally delay bremelanotide clearance. No published pharmacokinetic study has quantified this effect directly.

The Real Risk: Creatine Masking Renal Monitoring for Bremelanotide

This is the main safety concern clinicians should discuss with patients using both agents.

How Bremelanotide's Labeling Addresses Renal Function

The FDA-approved Vyleesi label states: "No dose adjustment is recommended in patients with mild or moderate renal impairment. Bremelanotide has not been studied in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m2) or end-stage renal disease, and use is not recommended in these patients." That sentence creates a clear clinical dependency: the prescriber needs a reliable eGFR to determine whether the drug is appropriate.

If creatine supplementation is artifactually depressing a patient's apparent eGFR, the prescriber may incorrectly place them in a more impaired renal category, potentially withholding a therapy or ordering unnecessary nephrology referrals.

The Reverse Problem: Missing True Renal Decline

A subtler risk runs in the opposite direction. If someone with early, true renal impairment is taking creatine and their creatinine happens to land in a range that looks acceptable, the creatine-related elevation and the disease-related elevation might partially cancel out in the clinician's interpretation. This scenario is unlikely in a young, otherwise healthy patient taking creatine for athletic performance, but worth naming.

Cystatin C as an Alternative Marker

Cystatin C, a protein filtered freely at the glomerulus, is not influenced by muscle mass or creatine intake. The CKD-EPI equation that incorporates cystatin C (CKD-EPI Cr-CysC) is considerably more accurate in muscular patients and in creatine users (pubmed.ncbi.nlm.nih.gov/22570462). Asking your prescriber to include a cystatin C level on your renal panel resolves most of the ambiguity created by creatine supplementation.

Cardiovascular Interactions: A Separate Concern

Bremelanotide carries a known transient blood pressure effect. In the RECONNECT trials, a mean maximum increase in systolic blood pressure of 6 mmHg was observed, peaking around 12 hours post-injection and resolving within 12 hours in most subjects. The label specifically contraindicates use in patients with established cardiovascular disease or uncontrolled hypertension.

Creatine monohydrate, at doses of 3 to 5 g/day used for maintenance, does not meaningfully alter blood pressure in normotensive adults. A 2021 meta-analysis in the Journal of the International Society of Sports Nutrition covering 12 trials found no statistically significant effect of creatine on resting systolic or diastolic BP (pubmed.ncbi.nlm.nih.gov/33992079). So cardiovascular additive effects are not a primary concern when combining standard-dose creatine with as-needed bremelanotide.

Who Should Be Most Cautious About Combining Both?

Most healthy adults have minimal risk from the combination. These groups warrant closer attention.

People with Pre-Existing Kidney Disease

Anyone with eGFR < 60 mL/min/1.73 m2 (CKD Stage 3 or worse) should avoid creatine supplementation in general. Adding bremelanotide on top of compromised kidneys, especially with the added creatinine burden from creatine, creates compounding uncertainty. The bremelanotide label's explicit caution against eGFR <30 is a hard stop.

Older Adults Using Off-Label Bremelanotide

Age-related decline in GFR is common and often asymptomatic. An older man using bremelanotide off-label for erectile dysfunction who also takes creatine for sarcopenia prevention presents the exact scenario where cystatin C-based eGFR monitoring is most valuable.

People on Other Nephrotoxic Agents

NSAIDs, certain antibiotics (aminoglycosides), and contrast agents all carry renal risk. Stacking bremelanotide, creatine, and a nephrotoxic NSAID taken regularly would be worth reviewing with a prescriber. The concern is cumulative renal stress, not a specific drug-supplement interaction.

Practical Guidance: How to Use Both Safely

The absence of a direct pharmacokinetic interaction means that for most people, concurrent use is manageable with simple precautions.

Step 1: Baseline Labs Before Starting

Order (or request) a comprehensive metabolic panel before initiating bremelanotide. Ideally include both serum creatinine-based eGFR and cystatin C. This gives the prescriber an accurate baseline that accounts for any creatine-related creatinine elevation.

Step 2: Disclose Creatine Use Explicitly

Tell your prescriber the exact dose and duration of creatine supplementation. A loading phase of 20 g/day produces a larger creatinine spike than 3 to 5 g/day maintenance dosing. That distinction affects how the lab result is interpreted.

Step 3: No Time-Separation Window Required

Unlike some supplement-drug pairs where dose timing matters (e.g., calcium and levothyroxine must be separated by 4 hours), no evidence supports separating creatine and bremelanotide doses by time. The concern is chronic lab interference, not an acute interaction at the time of injection.

Step 4: Repeat Renal Labs at 3 Months

If using bremelanotide regularly off-label over many weeks, a follow-up renal panel at 3 months confirms that real-world kidney function aligns with the baseline picture. This is standard monitoring practice in peptide therapy and does not require anything beyond a routine blood draw.

The HealthRX clinical team uses the following four-point framework when evaluating any supplement added to a peptide therapy regimen: (1) Does the supplement share the peptide's primary metabolic pathway? (2) Does the supplement alter any lab marker used to monitor the peptide's safety? (3) Does the supplement affect the same physiologic target as the peptide, producing additive or opposing effects? (4) Does the supplement interact with co-administered agents (e.g., cardiovascular medications taken alongside bremelanotide)? For creatine plus bremelanotide, the answers are no, yes, no, and context-dependent. That profile places this combination in the "low risk with monitoring" category rather than "avoid."

What the Evidence Does and Does Not Tell Us

No randomized controlled trial has co-administered creatine and bremelanotide and measured combined outcomes. That gap is not unusual. The FDA does not require drug-supplement interaction studies for approval, and bremelanotide's market is relatively small compared with drugs that generate large post-market pharmacovigilance datasets.

Guidance therefore rests on three pillars: (1) bremelanotide's pharmacokinetic profile from the FDA submission package, (2) creatine's well-characterized effect on serum creatinine from independent exercise science literature, and (3) general principles of renal monitoring in peptide therapeutics. The American College of Sports Medicine's 2021 updated consensus on dietary supplements states that creatine users should "inform their healthcare provider of supplementation status when kidney function is being assessed," an instruction directly applicable here (pubmed.ncbi.nlm.nih.gov/33009197).

The Endocrine Society's clinical practice guidelines on sexual dysfunction note that patient-reported supplement use should be part of the intake evaluation for any pharmacologic sexual health therapy (endocrine.org guidelines, doi: 10.1210/jc.2016-1128). Creatine fits that category.

Dosing Specifics: Does the Amount of Creatine Matter?

Yes. The creatinine-elevation effect is dose-dependent.

A maintenance dose of 3 to 5 g/day raises serum creatinine modestly, typically 0.05 to 0.10 mg/dL above baseline in adults with normal kidneys. A loading protocol of 20 g/day for 5 to 7 days can raise it by 0.15 to 0.22 mg/dL. For a 35-year-old man with a baseline creatinine of 1.05 mg/dL, a loading-phase spike could push him to 1.27 mg/dL, just above the normal threshold, prompting unnecessary concern if the prescriber is unaware.

Maintenance dosing during active bremelanotide use is a reasonable approach if athletic goals permit. If a loading phase is necessary (e.g., before a competitive season), completing it at least 2 to 3 weeks before scheduled renal lab work gives creatinine levels time to stabilize.

Summary of the Interaction Profile

| Parameter | Finding | |---|---| | Pharmacokinetic interaction | None identified | | Pharmacodynamic interaction | None identified | | Lab interference risk | Moderate (creatinine-based eGFR affected) | | Cardiovascular additive risk | Low at standard creatine doses | | Contraindication | None absolute for healthy adults | | Monitoring requirement | Baseline and follow-up renal panel | | Dose separation needed | No |

Creatine is generally safe. Bremelanotide is generally safe in its approved population. The overlap that requires clinical attention is narrow but real: keep your prescriber informed, get your kidney labs done with creatine use disclosed, and consider cystatin C if there is any doubt about the accuracy of your creatinine-based eGFR.